GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Price-to-Free-Cash-Flow

Integrated Biopharma (Integrated Biopharma) Price-to-Free-Cash-Flow : 21.82 (As of May. 09, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Price-to-Free-Cash-Flow?

As of today (2024-05-09), Integrated Biopharma's share price is $0.2182. Integrated Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Hence, Integrated Biopharma's Price-to-Free-Cash-Flow Ratio for today is 21.82.

The historical rank and industry rank for Integrated Biopharma's Price-to-Free-Cash-Flow or its related term are showing as below:

INBP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.6   Med: 7.33   Max: 120
Current: 21.82

During the past 13 years, Integrated Biopharma's highest Price-to-Free-Cash-Flow Ratio was 120.00. The lowest was 1.60. And the median was 7.33.

INBP's Price-to-Free-Cash-Flow is ranked worse than
54.17% of 1128 companies
in the Consumer Packaged Goods industry
Industry Median: 15.855 vs INBP: 21.82

Integrated Biopharma's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.04. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.01.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Integrated Biopharma was -92.10% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 0.90% per year.

During the past 13 years, Integrated Biopharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 171.40% per year. The lowest was -97.20% per year. And the median was 21.80% per year.


Integrated Biopharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Integrated Biopharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Price-to-Free-Cash-Flow Chart

Integrated Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 12.50 12.79 4.46 8.95

Integrated Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 2.39 8.95 5.71 24.52

Competitive Comparison of Integrated Biopharma's Price-to-Free-Cash-Flow

For the Packaged Foods subindustry, Integrated Biopharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma's Price-to-Free-Cash-Flow Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Price-to-Free-Cash-Flow falls into.



Integrated Biopharma Price-to-Free-Cash-Flow Calculation

Integrated Biopharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.2182/0.01
=21.82

Integrated Biopharma's Share Price of today is $0.2182.
Integrated Biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Integrated Biopharma  (OTCPK:INBP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Integrated Biopharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma (Integrated Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431